Prior to treatment (day 21 post-injection) with iNOP-7-PLK1 siRNA, all mice with similar whole body tumor luminescence (Supplementary Figure 7A) were randomized into treatment groups (n = 5-6 mice / group), and administered systemically with iNOP-7-PLK1 siRNA (1.25 mg/kg) or iNOP-7-control (Ctrl) siRNA (1.25 mg/kg) (days 23, 26, 29, 32 and 34). This evidence concerns the gene PLK1 and neoplasm.